Mesoblast (MESO) Posts Q1 Loss of 5c/Share

Mesoblast (NASDAQ: MESO) reported Q1 EPS of ($0.05), $0.30 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $395 thousand versus the consensus estimate of $3.69 thousand.

In line with previous guidance, the Company implemented operational streamlining measures during the quarter while achieving, and continuing to maintain progress towards, key milestones in its Tier 1 clinical programs.

For earnings history and earnings-related data on Mesoblast (MESO) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings